1) Researchers used virtual screening of over 4,000 compounds to identify potential dopamine D1 receptor ligands for treating schizophrenia. 2) In vitro testing of the 411 top-scoring compounds from virtual screening identified 172 hits with substantial D1 receptor affinity, a 42% hit rate. 3) One promising hit was a novel arylsulfonamide derivative (ADN-3772) that showed full D1 receptor affinity and potent partial agonist activity at the D2 receptor, suggesting potential as an antipsychotic agent.